Can evantumumab be used in patients with early-stage cancer?

Amivantamab (Amivantamab) is a bispecific antibody targeting EGFR and MET. It is mainly used to treat patients with < Patients with non-small cell lung cancer (NSCLC) with insertional mutations in /span>EGFRexon20. It inhibits tumor growth by blocking the EGFR and MET signaling pathways and enhances the immune system's clearance of cancer cells. Currently, the drug is mainly approved for the treatment of patients with advanced or metastatic non-small cell lung cancer, especially those whose disease has progressed after prior platinum-based chemotherapy.

For patients with early-stage cancer, the use of evantumumab is still under investigation. Current clinical data mainly focus on patients with advanced or recurrent NSCLC, while the efficacy and safety for patients with early-stage lung cancer (such as stages I-III) have not yet been fully established. Some studies are exploring the potential of evantumumab in the adjuvant or neoadjuvant setting, where the drug is given before or after surgery to reduce the risk of recurrence or improve cure rates, but these studies have not yet led to clear treatment guidelines.

In some cases, early-stage lung cancer patients carrying EGFRexon20 insertion mutations may benefit from targeted therapy, but the more commonly used treatment options are still surgery, radiation therapy and standard chemotherapy. For patients at high risk of recurrence, physicians may consider targeted therapy as an adjuvant approach, but whether to choose evantumumab still needs to be decided based on clinical trial data and individualized assessment.

In general, the current indications of evantumumab are mainly for patients with advanced NSCLCNSCLC, while its application in early-stage cancer is still in the exploratory stage. In the future, as more clinical studies are conducted, the drug may be incorporated into a wider range of treatment strategies, especially for early-stage lung cancer patients with specific genetic mutations.

Reference materials:https://www.rybrevant.com/